Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
Open Access
- 1 January 2019
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 36 (5), 589-594
- https://doi.org/10.5114/ada.2019.89507
Abstract
Introduction Antidrug antibody (ADA) production may be the reason behind secondary inefficacy of anti-TNF-α therapy in psoriasis. Aim To investigate the production of ADA, serum tumor necrosis factor α (TNF-α) and drug levels as predictors of clinical response in real-life circumstances....Keywords
This publication has 14 references indexed in Scilit:
- Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical responseJournal of International Medical Research, 2016
- Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)‐α level and the efficacy of TNF‐inhibitor therapy in psoriasisThe Journal of Dermatology, 2016
- Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategiesJournal of the European Academy of Dermatology and Venereology, 2014
- Antidrug antibodies in psoriasis: a systematic reviewBritish Journal of Dermatology, 2014
- Extent and Consequences of Antibody Formation Against Adalimumab in Patients With PsoriasisJAMA Dermatology, 2014
- Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicityArthritis & Rheumatism, 2012
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upPublished by American Medical Association (AMA) ,2011
- Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?Arthritis & Rheumatism, 2011
- Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot studyThe Journal of Dermatology, 2010
- Methotrexate reduces antibody responses to recombinant humanα-galactosidase A therapy in a mouse model of Fabry diseaseClinical and Experimental Immunology, 2004